Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Naiyer A. Rizvi, Matthew D. Hellmann, Alexandra Snyder et al. · Science · 2015 · 7.9K citations

Medicine, Immunology, Oncology +17

Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

Alexandra Snyder, Vladimir Makarov, Taha Merghoub et al. · New England Journal of Medicine · 2014 · 4.4K citations · Full text

Medicine, Immunology, Oncology +17

Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer

José Baselga, Javier Cortés, Sung‐Bae Kim et al. · New England Journal of Medicine · 2011 · 2.5K citations · Full text

Medicine, Oncology, Pharmacology +12

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

Luca Gianni, Tadeusz Pieńkowski, Young‐Hyuck Im et al. · The Lancet Oncology · 2011 · 2.4K citations

Medicine, Oncology, Pharmacology +16

Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer

Carsten Denkert, Sibylle Loibl, Aurelia Noske et al. · Journal of Clinical Oncology · 2009 · 1.8K citations

Life Sciences, Immunology, Oncology +17